JAMA Oncology: Is there a cure for AIDS and cancer?

JAMA Oncology: Is there a cure for AIDS and cancer?

June 13, 2019 Source: Sohu Health

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

At the recent annual meeting of the American Society of Clinical Oncology, Dr. Tom Uldrick of the Fred Hutchinson Cancer Research Center in the United States published a new study that can be used by patients with HIV and a variety of potentially fatal cancers. The PD-1 inhibitor pembrolizumab was treated.

If a person has both AIDS and cancer, is there still a rescue? The answer is: Yes!

This is one of two trials specifically targeted at HIV-infected people sponsored by the National Cancer Institute (NCI) and is the first prospective trial to report results. The trials were conducted at seven different cancer centers in the United States, including the National Cancer Institute's HIV and AIDS Malignancy segment.

The study has been published in the JAMA Oncology journal, and a total of 30 HIV-positive patients who may have adverse drug reactions were included in the trial. These patients also have different cancers, including lung cancer, Kaposi's sarcoma, non-Hodgkin's lymphoma, liver cancer, anal cancer, and advanced squamous cell carcinoma.

The “Adverse Event Profile” is an indicator of drug safety in this study. The researchers looked at whether patients developed gastrointestinal discomfort, rashes, and whether there was an extra T cell surge during treatment.

The study showed that the safety of the drug in HIV and cancer patients is similar to that in the general population clinical trials. In almost all cases, it is safe to use in both cancer and HIV patients.

Dr. Tom Uldrick believes that the findings may also be applicable to blocking five similar drugs called PD-1 or PD-L1 receptors on the surface of T cells.

However, there were also accidents in the study. A herpesvirus-associated B-cell lymphocyte proliferation and death occurred in a pre-treated herpesvirus patient. Currently, the link between death and treatment in this patient is unclear. To this end, the researchers warned that they should be highly cautious when using PD-1 inhibitors to treat Kaposi's sarcoma-associated herpesvirus-associated multicenter giant lymph node hyperplasia.

The researchers concluded that PD-1 inhibitors could be considered for HIV patients who are receiving antiretroviral therapy and have a CD4 count above a certain threshold (100 cells per microliter of blood). In the future, researchers will also conduct more research on the effectiveness of drugs.

Reference material

Https://

Https://

Https://jamanetwork.com/journals/jamaoncology/article-abstract/2735517

KN95 Mask

Kn95 Anti-Dust Face Mask,Kn95 Certification Respirator,Kn95 Certification Facemask,Kn95 Anti-Dust Disposable Face Mask

KUTA TECHNOLOGY INDUSTRY CO.,LIMITED , https://www.kutasureblue.com